Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Oct 7, 2022
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-10-05+25,000→ 25,000 totalExercise: $3.97From: 2023-10-05Exp: 2032-10-05→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date.